Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as ...

Eli Lilly will buy privately held SiteOne Therapeutics in a deal worth as much as $1 billion, the companies said on Tuesday, giving the drugmaker access to an experimental non-opioid pain medicine.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Net income attributable to SiteOne decreased $12.9 million to $44.4 million Adjusted EBITDA 1 decreased 4% to $114.8 million; Adjusted EBITDA margin was 9.5% Cash provided by operating activities ...

Eli Lilly is expanding its pain drug pipeline with the acquisition of SiteOne Therapeutics, a startup with a lead program that addresses the same target as a Vertex Pharmaceuticals product whose ...

Earnings Call Insights: SiteOne Landscape Supply, Inc. (SITE) Q1 2025 CEO Doug Black highlighted a solid start to 2025 with 4% net sales growth and 6% growth in adjusted EBITDA, despite ...

Throughout the last three months, 6 analysts have evaluated SiteOne Landscape Supply (NYSE:SITE), offering a diverse set of opinions from bullish to bearish. The table below offers a condensed ...

SiteOne Landscape Supply, Inc., together with its subsidiaries, engages in the wholesale distribution of landscape supplies in the United States and Canada. The company provides irrigation ...

The deal tees up a pain treatment market rivalry with Vertex Pharmaceuticals as the industry starts to move away from opioids.